Samuel Blackman
Oprichter bij DAY ONE BIOPHARMACEUTICALS, INC.
Vermogen: 28 M $ op 31-05-2024
Actieve functies van Samuel Blackman
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-11-2018 | - |
| Oprichter | 01-11-2018 | - | |
DOT Therapeutics-2, Inc.
 DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | Hoofd Techniek/Wetenschap/O&O | - | - |
| Oprichter | - | - |
Loopbaan van Samuel Blackman
Eerdere bekende functies van Samuel Blackman
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Mavupharma, Inc.
 Mavupharma, Inc. Pharmaceuticals: MajorHealth Technology Mavupharma, Inc. engages development of non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease. The company was founded by W. Michael Gallatin, Brian K. Farmer, and Robert F. Baltera, Jr. and is headquartered in Kirkland, WA. | Corporate Officer/Principal | 01-09-2018 | 01-07-2019 |
| ARS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-08-2016 | 01-09-2018 |
| JUNO THERAPEUTICS INC | Hoofd Techniek/Wetenschap/O&O | 01-06-2014 | 01-08-2016 |
Opleiding van Samuel Blackman
| University of Illinois | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 7 |
Operationeel
| Chief Tech/Sci/R&D Officer | 3 |
| Founder | 2 |
| Corporate Officer/Principal | 2 |
Sectoraal
| Health Technology | 6 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | Health Technology |
Mavupharma, Inc.
Mavupharma, Inc. Pharmaceuticals: MajorHealth Technology Mavupharma, Inc. engages development of non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease. The company was founded by W. Michael Gallatin, Brian K. Farmer, and Robert F. Baltera, Jr. and is headquartered in Kirkland, WA. | Health Technology |
Silverback Therapeutics, Inc.
 Silverback Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The company was founded by Peter A. Thompson January 4, 2016 and is headquartered in Seattle, WA. | Health Technology |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
- Beurs
- Insiders
- Samuel Blackman
- Ervaring
